| abstract |
The disclosure relates to methods for treating acute respiratory distress syndrome (ARDS), acute lung inflammation (ALI), acute lung injury and/or cardiac injury (e.g., acute cardiac injury), treating an infection, reducing pathogen burden and/or inhibiting pathogen replication by administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor. In some aspects, the subject is infected with a respiratory pathogen and has influenza, SARS, MERS or COVID-19. |